Anti-rhesus D prophylaxis in pregnant women is based on sialylated IgG antibodies

F1000Research

Volumn 2, Issue , 2013, Pages

  Ehlers, Marc ^a,b   Winkler, André ^a,b   Berger, Markus ^c  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; RHESUS D ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ACTIVITY; ERYTHROCYTE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; PREGNANT WOMAN; RHESUS IMMUNIZATION; RHEUMATOID ARTHRITIS; SIALYLATION; T LYMPHOCYTE;

EID: 84907598127     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.2-169.v1     Document Type: Article

References (34)

1. Kumpel BM: Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn. Clin Exp Immunol. 2008;154(1):1-5. 18727626 10.1111/j.1365-2249.2008.03735.x 2561090
2. Kumpel BM Elson CJ: Mechanism of anti-D-mediated immune suppression--a paradox awaiting resolution? Trends Immunol. 2001;22(1):26-31. 11286688 10.1016/S1471-4906(00)01801-9
3. Kumpel BM: In vivo studies of monoclonal anti-D and the mechanism of immune suppression. Transfus Clin Biol. 2002;9(1):9-14. 11889904 10.1016/S1246-7820(01)00209-9
4. Kumpel BM: Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang. 2007;93(2):99-111. 17683353 10.1111/j.1423-0410.2007.00945.x
5. Stott LM Barker RN Urbaniak SJ: Identification of alloreactive T-cell epitopes on the Rhesus D protein. Blood. 2000;96(13):4011-4019. 11110668
6. Hall AM Cairns LS Altmann DM: Immune responses and tolerance to the RhD blood group protein in HLA-transgenic mice. Blood. 2005;105(5):2175-2179. 15383466 10.1182/blood-2004-04-1554
7. Döbel T Kunze A Babatz J: FcγRIII (CD16) equips immature 6-sulfo LacNAc-expressing dendritic cells (slanDCs) with a unique capacity to handle IgG-complexed antigens. Blood. 2013;121(18):3609-3618. 23460612 10.1182/blood-2012-08-447045
8. Kumpel BM Goodrick MJ Pamphilon DH: Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D- volunteers. Blood. 1995;86(5):1701-1709. 7655002
9. Shinkawa T Nakamura K Yamane N: The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278(5):3466-3473. 12427744 10.1074/jbc.M210665200
10. Nimmerjahn F Ravetch JV: Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005;310(5753):1510-1512. 16322460 10.1126/science.1118948
11. Ercan A Cui J Chatterton DE: Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010;62(8):2239-2248. 20506563 10.1002/art.27533
12. Rademacher TW Williams P Dwek RA: Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc Natl Acad Sci U S A. 1994;91(13):6123-6127. 8016124 10.1073/pnas.91.13.6123 44150
13. Parekh RB Dwek RA Sutton BJ: Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985;316(6027):452-457. 3927174 10.1038/316452a0
14. Scherer HU van der Woude D Ioan-Facsinay A: Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum. 2010;62(6):1620-1629. 20178128 10.1002/art.27414
15. Rook GA Steele J Brealey R: Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun. 1991;4(5):779-794. 1797027 10.1016/0896-8411(91)90173-A
16. Van Beneden K Coppieters K Laroy W: Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann Rheum Dis. 2009;68(8):1360-1365. 18772190 10.1136/ard.2008.089292
17. Kaneko Y Nimmerjahn F Ravetch JV: Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313(5787):670-673. 16888140 10.1126/science.1129594
18. Arnold JN Wormald MR Sim RB: The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21-50. 17029568 10.1146/annurev.immunol.25.022106.141702
19. Nimmerjahn F Ravetch JV: Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513-533. 18370923 10.1146/annurev.immunol.26.021607.090232
20. Anthony RM Kobayashi T Wermeling F: Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;475(7354):110-113. 21685887 10.1038/nature10134 3694429
21. Oefner CM Winkler A Hess C: Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J Allergy Clin Immunol. 2012;129(6):1647-1655. 22502800 10.1016/j.jaci.2012.02.037
22. Collin M Ehlers M: The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies. Exp Dermatol. 2013;22(8):511-4. 23808883 10.1111/exd.12171
23. Hess C Winkler A Lorenz AK: T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. J Clinical Invest. accepted.
24. Karsten CM Pandey MK Figge J: Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of Fc gamma RIIB and dectin-1. Nat Med. 2012;18(9):1401-1406. 22922409 10.1038/nm.2862 3492054
25. Ackerman ME Crispin M Yu X: Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest. 2013;123(5):2183-2192. 23563315 10.1172/JCI65708 3637034
26. Kumpel BM Rademacher TW Rook GA: Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum Antibodies Hybridomas. 1994;5(3-4):143-151. 7756579
27. Kumpel BM Wang Y Griffiths HL: The biological activity of human monoclonal IgG anti-D is reduced by beta-galactosidase treatment. Hum Antibodies Hybridomas. 1995;6(3):82-88. 8597627
28. Sibéril S de Romeuf C Bihoreau N: Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin Immunol. 2006;118(2-3):170-179. 16332457 10.1016/j.clim.2005.10.008
29. Beliard R Waegemans T Notelet D: A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol. 2008;141(1):109-119. 18279459 10.1111/j.1365-2141.2008.06985.x
30. PCT/FR2010/050376 (international publication number: WO/2010/100383) Anti-rhesus d monoclonal antibody. Reference Source
31. US 7931895 B2 patent "Monoclonal antibodies with enhanced ADCC function?; issued 2011. Reference Source
32. Yver A Homery MC Fuseau E: Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCγRIII, in healthy volunteers. Vox Sang. 2012;103(3):213-222. 22568808 10.1111/j.1423-0410.2012.01603.x
33. Beck A Reichert JM: Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs. 2012;4(4):419-425. 22699226 10.4161/mabs.20996 3499336
34. Collin M Olsén A: Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins. Infect Immun. 2001;69(11):7187-7189. 11598100 10.1128/IAI.69.11.7187-7189.2001 100124